仑卡奈单抗可减少脑内淀粉样蛋白-β 并延缓认知能力下降。
Lecanemab reduces brain amyloid-β and delays cognitive worsening.
机构信息
Department of Neurology and Mayo Clinic Alzheimer Research Center, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Cell Rep Med. 2023 Mar 21;4(3):100982. doi: 10.1016/j.xcrm.2023.100982.
Abstract
Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
摘要
van Dyck 等人报告的一项为期 18 个月的双盲随机安慰剂对照试验显示，仑卡奈单抗清除了三分之二的淀粉样蛋白-β，降低了轻度认知障碍和轻度阿尔茨海默病性痴呆患者认知和功能恶化的速度。
相似文献
1
Lecanemab reduces brain amyloid-β and delays cognitive worsening.仑卡奈单抗可减少脑内淀粉样蛋白-β 并延缓认知能力下降。
Cell Rep Med. 2023 Mar 21;4(3):100982. doi: 10.1016/j.xcrm.2023.100982.
2
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.利斯卡尼单抗治疗早期阿尔茨海默病患者：来自 2 期概念验证研究随机和开放标签扩展的生物标志物、认知和临床效果的详细结果。
Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.
3
Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?仑卡奈单抗获批用于阿尔茨海默病患者治疗的影响：是增量步骤还是范式转变？
Neurology. 2023 Oct 3;101(14):610-620. doi: 10.1212/WNL.0000000000207438. Epub 2023 Jun 9.
4
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.利斯的明透皮贴剂（Leqembi）并不适合阿尔茨海默病患者。
Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.
5
Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.在无痴呆的帕金森病中，局部脑区淀粉样β蛋白积聚与特定领域的认知表现相关。
PLoS One. 2017 May 25;12(5):e0177924. doi: 10.1371/journal.pone.0177924. eCollection 2017.
6
Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.阿尔茨海默病和轻度认知障碍患者脑淀粉样蛋白-β与脑灌注和结构的关系。
Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.
7
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.认知和神经影像学特征以及阿尔茨海默病风险个体的脑β-淀粉样蛋白（INSIGHT-preAD）：一项纵向观察性研究。
Lancet Neurol. 2018 Apr;17(4):335-346. doi: 10.1016/S1474-4422(18)30029-2. Epub 2018 Feb 27.
8
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.阿尔茨海默病中萎缩与β-淀粉样蛋白沉积的关系。
Ann Neurol. 2010 Mar;67(3):317-24. doi: 10.1002/ana.21955.
9
Associations of Widowhood and β-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults.丧偶和β-淀粉样蛋白与认知正常老年人认知能力下降的关系。
JAMA Netw Open. 2020 Feb 5;3(2):e200121. doi: 10.1001/jamanetworkopen.2020.0121.
10
Amyloid pathology in the progression to mild cognitive impairment.淀粉样蛋白病理学在向轻度认知障碍的进展中。
Neurobiol Aging. 2018 Apr;64:76-84. doi: 10.1016/j.neurobiolaging.2017.12.018. Epub 2017 Dec 27.
引用本文的文献
1
Epigenetic Dysregulation in Neurodegenerative Disease: Implications for Neuropathology and Therapy.神经退行性疾病中的表观遗传失调：对神经病理学和治疗的影响
Cureus. 2025 Aug 15;17(8):e90188. doi: 10.7759/cureus.90188. eCollection 2025 Aug.
2
β-Amyloid induces microglial expression of GPC4 and APOE leading to increased neuronal tau pathology and toxicity.β-淀粉样蛋白诱导小胶质细胞表达磷脂酰肌醇蛋白聚糖4（GPC4）和载脂蛋白E（APOE），导致神经元tau蛋白病变和毒性增加。
Mol Neurodegener. 2025 Aug 29;20(1):96. doi: 10.1186/s13024-025-00883-4.
3
Fyn-ding Novel Therapeutic Targets for Temporal Lobe Epilepsy-Unlikely Partners at the Hippocampal Synapse.寻找颞叶癫痫的新型治疗靶点——海马突触中不太可能的伙伴
Epilepsy Curr. 2025 Apr 30:15357597251335683. doi: 10.1177/15357597251335683.
4
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model.载脂蛋白E缺乏抑制淀粉样蛋白促进的（A）tau病理（T）和神经退行性变（N），在临床前模型中阻止进行性ATN病理。
Mol Psychiatry. 2025 Apr 30. doi: 10.1038/s41380-025-03036-7.
5
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease.莱卡奈单抗优先结合早期阿尔茨海默病中存在的较小聚集体。
Alzheimers Dement. 2025 Apr;21(4):e70086. doi: 10.1002/alz.70086.
6
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center.在区域医疗中心的 71 例患者中应用 Lecanemab 的初步经验和教训。
J Prev Alzheimers Dis. 2024;11(6):1549-1562. doi: 10.14283/jpad.2024.159.
7
Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy.功能与生存的联合评估以证明治疗对进行性核上性麻痹的效果
Mov Disord. 2025 Jan;40(1):97-107. doi: 10.1002/mds.30027. Epub 2024 Oct 29.
8
Insights into the use of biomarkers in clinical trials in Alzheimer's disease.浅析生物标志物在阿尔茨海默病临床试验中的应用。
EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3.
9
Active Immunotherapy for the Prevention of Alzheimer's and Parkinson's Disease.用于预防阿尔茨海默病和帕金森病的主动免疫疗法。
Vaccines (Basel). 2024 Aug 28;12(9):973. doi: 10.3390/vaccines12090973.
10
Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease.调节淀粉样蛋白和 Tau 蛋白聚集以减轻阿尔茨海默病转基因小鼠模型中的认知障碍
ACS Pharmacol Transl Sci. 2024 Jun 26;7(9):2650-2661. doi: 10.1021/acsptsci.4c00006. eCollection 2024 Sep 13.
本文引用的文献
1
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
2
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.利斯卡尼单抗治疗早期阿尔茨海默病患者：来自 2 期概念验证研究随机和开放标签扩展的生物标志物、认知和临床效果的详细结果。
Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究：阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
5
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.阿尔茨海默病中的淀粉样蛋白假说：新疗法的新见解。
Nat Rev Drug Discov. 2022 Apr;21(4):306-318. doi: 10.1038/s41573-022-00391-w. Epub 2022 Feb 17.
6
Distinct conformers of amyloid beta accumulate in the neocortex of patients with rapidly progressive Alzheimer's disease.在快速进展性阿尔茨海默病患者的大脑新皮层中，淀粉样β蛋白的不同构象聚集。
J Biol Chem. 2021 Nov;297(5):101267. doi: 10.1016/j.jbc.2021.101267. Epub 2021 Sep 30.
7
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
8
Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease.基于患者中心的连接性预测阿尔茨海默病tau 病理扩散。
Sci Adv. 2020 Nov 27;6(48). doi: 10.1126/sciadv.abd1327. Print 2020 Nov.
9
Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease.病理性 tau 蛋白在人类阿尔茨海默病中通过神经元间的传递而扩散。
Nat Commun. 2020 May 26;11(1):2612. doi: 10.1038/s41467-020-15701-2.
10
Impact of multiple pathologies on the threshold for clinically overt dementia.多种病变对临床显性痴呆阈值的影响。
Acta Neuropathol. 2017 Aug;134(2):171-186. doi: 10.1007/s00401-017-1717-7. Epub 2017 May 9.
Zotero 插件